BOLT Stock Price, Bolt Biotherapeutics, . Quote, Chart

Market Summary

USD0.80-0.02

Delayed

-2.44%

BOLT Stock Price

View Fullscreen

BOLT RSI Chart

BOLT Valuation

Market Cap

30.5M

Price/Earnings (Trailing)

-0.48

Price/Sales (Trailing)

2.69

Price/Free Cashflow

-0.48

BOLT Price/Sales (Trailing)

BOLT Profitability

Return on Equity

-60.51%

Return on Assets

-44.11%

Free Cashflow Yield

-206.8%

BOLT Fundamentals

BOLT Revenue

Revenue (TTM)

11.3M

Rev. Growth (Yr)

48.05%

Rev. Growth (Qtr)

-17.37%

BOLT Earnings

Earnings (TTM)

-63.0M

Earnings Growth (Yr)

36.33%

Earnings Growth (Qtr)

39.61%

Breaking Down BOLT Revenue

Last 7 days

-36.5%

Last 30 days

-27.9%

Last 90 days

-33.3%

Trailing 12 Months

-57.9%

How does BOLT drawdown profile look like?

BOLT Financial Health

Current Ratio

5.68

BOLT Investor Care

Shares Dilution (1Y)

0.83%

Diluted EPS (TTM)

-1.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	11.3M	0	0	0
2023	6.7M	6.8M	7.2M	7.9M
2022	2.2M	3.5M	4.8M	5.7M
2021	0	269.0K	970.0K	1.4M
2020	0	0	0	257.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Bolt Biotherapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 12, 2023	quinn william p.	bought	7,125	0.95	7,500	chief financial officer
Dec 06, 2023	quinn william p.	bought	1,955	0.782	2,500	chief financial officer
Dec 06, 2023	perez edith a.	bought	1,955	0.782	2,500	chief medical officer
Dec 06, 2023	yonehiro grant	bought	1,955	0.782	2,500	chief business officer
Dec 06, 2023	schatzman randall c	bought	1,955	0.782	2,500	chief executive officer
Nov 30, 2023	engleman edgar	sold	-92,799	0.8581	-108,145	-
Nov 30, 2023	engleman edgar	sold	-12,814	0.8581	-14,934	-
Nov 29, 2023	engleman edgar	sold	-20,542	0.906	-22,674	-
Nov 29, 2023	engleman edgar	sold	-2,836	0.906	-3,131	-
Nov 21, 2023	vivo capital viii, llc	sold	-1,536	0.9	-1,707	-

Which funds bought or sold BOLT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-63,016	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-32.66	-1,460	7,764	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-1.76	627,986	3,382,020	-%
May 15, 2024	Royal Bank of Canada	reduced	-99.78	-	-	-%
May 15, 2024	ORBIMED ADVISORS LLC	unchanged	-	431,480	2,157,400	0.04%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	31,136	155,680	-%
May 15, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	unchanged	-	140,000	700,000	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	reduced	-6.36	697,487	4,788,000	0.50%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-2.24	11,690	64,338	-%
May 15, 2024	Board of Trustees of The Leland Stanford Junior University	unchanged	-	201,473	1,007,360	0.09%

Are Funds Buying or Selling BOLT?

Are funds buying BOLT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BOLT

No. of Funds

Unveiling Bolt Biotherapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	tang capital partners lp	9.6%	3,652,244	SC 13G/A
Feb 14, 2024	citadel advisors llc	6.2%	6	SC 13G/A
Feb 13, 2024	vivo capital viii, llc	4.8%	1,821,483	SC 13G/A
Feb 12, 2024	pivotal bioventure partners fund i, l.p.	8.1%	3,058,419	SC 13D/A
Apr 20, 2023	tang capital partners lp	7.2%	2,732,250	SC 13G
Feb 14, 2023	citadel advisors llc	7.3%	6	SC 13G/A
Feb 13, 2023	suvretta capital management, llc	0%	0	SC 13G/A
Jan 04, 2023	novo holdings a/s	0%	0	SC 13D/A
Dec 28, 2022	novo holdings a/s	6.7%	2,534,465	SC 13D/A
Jul 15, 2022	novo holdings a/s	9.8%	3,703,991	SC 13D/A

Recent SEC filings of Bolt Biotherapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	3	Insider Trading
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 21, 2024	S-8	Employee Benefits Plan
Mar 21, 2024	10-K	Annual Report
Mar 21, 2024	8-K	Current Report
Mar 06, 2024	4	Insider Trading

Peers (Alternatives to Bolt Biotherapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Bolt Biotherapeutics, Inc. News

Latest updates

Bolt Biotherapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	152.5%	5,274	2,089	2,528	1,433	1,826	1,411	2,112	1,393	813	508	752	176	-	42.00	51.00	164
Operating Expenses	2.3%	22,366	21,855	20,711	21,265	20,241	22,451	24,458	24,452	24,689	27,583	24,278	23,761	16,922	12,405	11,177	8,909
S&GA Expenses	-100.0%	-	5,533	5,760	5,621	5,616	5,606	5,485	5,532	6,304	5,099	4,941	4,054	2,058	2,865	2,011	2,122
R&D Expenses	1.3%	16,529	16,322	14,951	15,644	14,625	16,845	18,973	18,920	18,385	22,484	19,337	19,707	14,864	9,540	9,166	6,787
Net Income	39.6%	-10,811	-17,903	-16,257	-18,057	-16,980	-19,997	-21,759	-22,664	-23,678	-27,157	-23,395	-23,585	-31,035	-10,001	-11,059	-8,633
Net Income Margin	36.6%	-5.57*	-8.79*	-9.90*	-11.32*	-12.07*	-15.38*	-19.74*	-27.96*	-43.49*	-68.66*	-105.64*	-331.13*	-	-	-	-
Free Cashflow	-17.4%	-16,751	-14,271	-16,914	-15,144	-23,402	-18,136	-14,186	-21,216	-24,919	-18,356	-19,742	-4,689	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-10.6%	143	160	175	191	206	228	246	260	283	308	334	347	325	47.00
Current Assets	-10.1%	95.00	106	125	131	132	173	175	181	196	189	222	248	271	25.00
Cash Equivalents	-60.6%	4.00	11.00	9.00	13.00	15.00	9.00	11.00	23.00	44.00	27.00	24.00	58.00	95.00	6.00
Net PPE	-9.2%	4.00	5.00	5.00	6.00	6.00	6.00	7.00	7.00	7.00	6.00	6.00	5.00	4.00	4.00
Liabilities	-17.7%	39.00	47.00	47.00	49.00	48.00	56.00	57.00	52.00	54.00	58.00	59.00	51.00	21.00	46.00
Current Liabilities	-18.2%	17.00	20.00	19.00	18.00	16.00	23.00	24.00	19.00	19.00	21.00	24.00	19.00	12.00	11.00
Shareholder's Equity	-7.6%	104	113	128	142	158	172	188	208	228	250	275	296	303	-
Retained Earnings	-3.0%	-375	-364	-346	-330	-312	-295	-275	-253	-230	-206	-179	-156	-132	-108
Additional Paid-In Capital	0.5%	479	477	475	472	470	468	465	463	460	457	455	452	436	3.00
Shares Outstanding	0.0%	38.00	38.00	38.00	38.00	38.00	38.00	37.00	37.00	37.00	37.00	32.00	29.00	21.00	-
Float	-	-	-	-	32.00	-	-	-	51.00	-	-	-	383	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-17.4%	-16,751	-14,265	-16,749	-15,112	-23,399	-17,952	-13,451	-20,787	-24,314	-17,794	-18,727	-3,986	-16,559	-12,890	-12,515	-12,265	-9,638
Share Based Compensation	-47.3%	2,302	4,372	33.00	39.00	2,476	4,290	100	100	2,919	4,167	100	100	2,109	569	403	223	225
Cashflow From Investing	-35.5%	10,203	15,809	12,658	13,580	28,991	16,435	1,450	-868	40,845	21,033	-16,111	-46,602	-190,521	1,704	-13,095	4,407	-13,608
Cashflow From Financing	-100.0%	-	106	-	-	-	144	-	252	107	495	185	13,409	297,019	-1,065	-923	41,551	34.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BOLT Income Statement

2024-03-31

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue	$ 5,274	$ 1,826
Operating expenses:
Research and development	16,529	14,625
General and administrative	5,837	5,616
Total operating expense	22,366	20,241
Loss from operations	(17,092)	(18,415)
Other income, net
Interest income, net	1,606	1,435
Other income	4,675
Total other income, net	6,281	1,435
Net loss	(10,811)	(16,980)
Net unrealized (loss) gain on marketable securities	(73)	684
Comprehensive loss	$ (10,884)	$ (16,296)
Net loss per share, basic	$ (0.28)	$ (0.45)
Net loss per share, diluted	$ (0.28)	$ (0.45)
Weighted-average shares outstanding, basic	38,068,424	37,684,023
Weighted-average shares outstanding, diluted	38,068,424	37,684,023

BOLT Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,262	$ 10,810
Short-term investments	87,088	91,379
Prepaid expenses and other current assets	3,705	3,519
Total current assets	95,055	105,708
Property and equipment, net	4,499	4,957
Operating lease right-of-use assets	18,347	19,120
Restricted cash	1,765	1,765
Long-term investments	21,461	26,413
Other assets	1,765	1,821
Total assets	142,892	159,784
Current liabilities:
Accounts payable	2,219	2,987
Accrued expenses and other current liabilities	9,710	12,486
Deferred revenue	1,907	2,201
Operating lease liabilities	2,887	2,782
Total current liabilities	16,723	20,456
Operating lease liabilities, net of current portion	16,680	17,437
Deferred revenue, non-current	5,330	9,107
Other long-term liabilities	0	43
Total liabilities	38,733	47,043
Commitments and contingencies (Note 7)
Stockholders' equity (deficit):
Preferred stock, $0.00001 par value, authorized shares-10,000,000 shares authorized at March 31, 2024 and December 31, 2023; zero shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.00001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 38,127,740 and 38,114,606 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1	1
Additional paid-in capital	479,290	476,988
Accumulated other comprehensive (loss) gain	(36)	37
Accumulated deficit	(375,096)	(364,285)
Total stockholders' equity:	104,159	112,741
Total liabilities and stockholders' equity	$ 142,892	$ 159,784

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

CEO	Dr. Randall C. Schatzman Ph.D.
WEBSITE	boltbio.com
INDUSTRY	Biotechnology
EMPLOYEES	94

Bolt Biotherapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Bolt Biotherapeutics, Inc.? What does BOLT stand for in stocks?

BOLT is the stock ticker symbol of Bolt Biotherapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bolt Biotherapeutics, Inc. (BOLT)?

As of Fri May 17 2024, market cap of Bolt Biotherapeutics, Inc. is 30.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BOLT stock?

You can check BOLT's fair value in chart for subscribers.

What is the fair value of BOLT stock?

You can check BOLT's fair value in chart for subscribers. The fair value of Bolt Biotherapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bolt Biotherapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BOLT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bolt Biotherapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether BOLT is over valued or under valued. Whether Bolt Biotherapeutics, Inc. is cheap or expensive depends on the assumptions which impact Bolt Biotherapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BOLT.

What is Bolt Biotherapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BOLT's PE ratio (Price to Earnings) is -0.48 and Price to Sales (PS) ratio is 2.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BOLT PE ratio will change depending on the future growth rate expectations of investors.